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Well-recognized experts in the field of gastric cancer discussed during the 12th European Society Medical Oncology
(ESMO)/World Congress Gastrointestinal Cancer (WCGIC) in Barcelona many important and controversial topics on
the diagnosis and management of patients with gastric cancer. This article summarizes the recommendations and
expert opinion on gastric cancer. It discusses and reflects on the regional differences in the incidence and care of
gastric cancer, the definition of gastro-esophageal junction and its implication for treatment strategies and presents
the latest recommendations in the staging and treatment of primary and metastatic gastric cancer. Recognition is
given to the need for larger and well-designed clinical trials to answer many open questions.
methods
At the 2010 Barcelona European Society Medical Oncology/World
Congress Gastrointestinal Cancer (ESMO/WCGIC) meeting a panel of
invited experts involved in the care of gastric cancer conducted a structured
discussion on the different aspects of gastric cancer care. The panel is
composed of experts from the different disciplines involved in the care of
gastric cancer: gastroenterologists, medical oncologists, radiation
oncologists and oncological surgeons. Experts were selected on their
scientific merits and their recognition as international opinion leaders. The
panel was presented with a detailed questionnaire prior to the meeting.
Answers are summarized and then discussed in an extended forum.
Conclusions of the recommendations and expert opinion are based on the
published data and on clinical experience. The expert opinion
recommendations do not therefore represent an official guideline or true
consensus statements. The publication aims to guide clinicians in the hands
on decisions encountered in the management of gastric cancer.
introduction
Gastric adenocarcinomas are anatomically divided into true
gastric cancer, also referred as gastric, non-cardia cancers,
which still comprises the majority of cases, and gastro-
esophageal junction (GEJ) adenocarcinomas, also referred as
proximal gastric or cardia carcinomas. The GEJ cancers and
non-GEJ cancers clearly vary in incidence trends, geographical
distrubition, proposed etiology, clinical presentation and
treatment strategies.
Gastric carcinoma is the fourth most common malignancy
worldwide [1] and it is the second most common cause of
death [2]. Incidence varies greatly across the different world
regions with a predominance of 26.9 per 100 000 per year (PY)
in Asian males as opposed to 7.4 per 100 000 PY in their North
American counterparts [1]. The decrease in incidence described
in the past few decades reflects mainly the decrease in non-
cardia cancers while the GEJ cancers are stable or even clearly
more frequent in some parts of the world [3–4]. A recent
account of the trends in the USA gathered from the
Surveillance, Epidemiology and End Results (SEER) data
s
y
m
p
o
s
iu
m
a
rt
ic
le
*Correspondence to: Professor Eric Van Cutsem, Digestive Oncology, University
Hospital Gasthuisberg, Leuven, Belgium. Tel: +32-16-344218;
E-mail: Eric.VanCutsem@uzleuven.be
ª The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oup.com
between 1977 and 2006 revealed a decline in the rate of non-
cardia carcinomas among all race and age groups except for
whites aged 25–39 years, where an increase in incidence rate
was seen. No clear explanation for this phenomenon is yet
available [5].
It is believed that the different trends in the incidence rates
in the different geographical regions, as well as the different
trends in the anatomical localization of gastric
adenocarcinomas are rooted in the rate of exposure to the
various causal factors. Non-cardia tumors are attributed to
lower socioeconomic background, exposure to Helicobacter
pylori (HP) infection, smoking, high intake of salty and
smoked food and a low intake of fresh fruit and vegetables.
The decrease in its incidence is attributed to the decrease in
exposure to these risk factors, with better food preservation,
reduced smoking, increased consumption of fresh food and
very importantly a decrease in HP infection rates [6–8]. Risk
factors related to cardia cancers include gastro-esophageal
reflux disease (GERD), male gender, white race, smoking and
obesity [9–12]. The association of GEJ adenocarcinomas with
HP infection remains unclear with conflicting reports of
a possible protective role [13–14].
Additional risk factors include atrophic gastritis, familial
clustering and genetic syndromes, such as Lynch’s syndrome
[hereditary non-polyposis colorectal cancer (HNPCC)
syndrome].
Survival rates from gastric cancer have improved over the last
few decades. Five-year overall survival (OS) in the Western
world is estimated at 20%. Fewer patients are referred for
surgery, but those who undergo resection have a higher survival
rate, which reaches 50%, possibly due to more accurate
preoperative staging and improved imaging techniques. In Asia
large-scale screening programs, detection at earlier stages and
more aggressive surgical approaches, including more frequent
D2 lymph node resection, contribute to high OS rates of 60%
[15–17].
Treatment strategies in gastric cancer incorporate
a multidisciplinary approach and require the co-operation of
gastroenterologists, surgeons, medical and radiation
oncologists, pathologists and radiologists. Great importance for
optimal outcome is given to referral and treatment in high-
volume centers that can incorporate all these different
disciplines [18, 19].
familial predisposition
Several syndromes are associated with familial predisposition of
gastric cancer. These can be divided according to the histology
such as familial diffuse gastric cancer, which is associated in
25% of cases with a germline E-cadherin/CDH1 mutation
and familial intestinal gastric cancer. Further specific genetic
syndromes are also associated with an increased gastric cancer
risk, mainly Lynch’s (HNPCC) syndrome, but also others, such
as Li–Fraumeni syndrome, familial adenomatous polyposis
(FAP) syndrome and Peutz–Jeghers syndrome [17].
An occurrence of two or more cases of gastric cancer in the
family, especially of the diffuse type in young individuals,
should prompt reference for genetic counseling and a search for
E-cadherin mutation and HNPCC syndrome (see
recommendations in Figure 1). E-cadherin carriers are
recommended to undergo regular gastroscopies, every 1–2
years at least from the age of 40 or earlier, specifically if cancers
occurred at a young age in the family. Preventive gastrectomy
should be considered.
With familial predisposition, HP screening and eradication is
advised. In countries with a high incidence of gastric cancer,
such as Japan or Korea, familial clustering is sufficient to
implement yearly screening gastroscopy.
HP eradication
The correlation between HP infection and the incidence of
gastric cancer has been demonstrated by several epidemiologic
studies [20–22]. However, no clear benefit is seen with HP
eradication for primary prevention of gastric cancer. A
systematic review of the literature on the prevention of gastric
cancer by HP eradication recently published by Takata et al.
[23] suggested that HP eradication can decrease the gastric
cancer prevalence by a third, but this observation is supported
only by Japanese publications and not by those in other regions.
Which advice for patients with familial predisposition? 
•
•
•
Search for E-cadherin mutation and HNPCC syndrome 
Search for E-cadherin in families with 2 cases (with diffuse-type gastric cancer), especially 
at younger age 
•
•
HP screening and eradication 
In Japan and Korea: gastroscopy every year in patients with familial incidence 
Genetic counseling 
Gastroscopy every 1–2 years (some specified after age 40) in E-cadherin mutation carriers 
Consider gastrectomy in selected patients with E-cadherin mutation 
Figure 1. Recommendations for evaluation in suspected familial predisposition of gastric cancer.
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Further randomized trials examining the impact of systemic HP
eradication in high-risk regions are ongoing. The eradication of
HP in patients without underlying premalignant conditions is
not generally recommended at present.
Fukase et al. [24] performed a randomized controlled trial
investigating the need for HP eradication after endoscopic
mucosal resection (EMR) of early gastric cancer. Eradication
resulted in odds ratio for metachronous gastric carcinoma of
0.353 (P = 0.009) for the intent to treat group. No randomized
trials examined the need for eradication after partial
gastrectomy, though an evaluation of the gastric mucosa in
patients undergoing partial gastrectomy for early cancer
revealed a reduction in mucosal damage of potential pre-
cancerous risk [25]. HP eradication is recommended following
resection of gastric cancer by EMR or partial gastrectomy.
staging
The diagnosis of gastric adenocarcinoma has to be confirmed
by biopsies, performed during upper gastrointestinal
endoscopy. Accurate staging is very important since it
determines the treatment strategy as well as the outcome of
patients with gastric cancer.
A general clinical evaluation, including organ function, is
warranted in every patient with gastric cancer. The most useful
serum tumor markers are carcinoembryonic antigen (CEA) and
CA19-9. Preoperative marker levels have a prognostic value. In
a large study, preoperative CEA level was elevated in 249
(28.8%) out of 865 patients with gastric cancer. The CEA levels
significantly correlated with stage and a multivariate analysis
showed a significant correlation with survival. A significant
difference was seen between patients with CEA levels <10 ng/ml
as opposed to those >10 ng/ml [26]. A few smaller studies
suggested a prognostic role for preoperative CA72.4 levels [27–
29]. In general CEA and CA19-9 levels are determined
preoperatively in patients with resectable gastric cancer and the
marker if initially elevated, is used in the surveillance of these
patients.
Available imaging techniques include endoscopic ultrasound
(EUS), computerized tomography (CT), magnetic resonance
imaging (MRI) and fluorodeoxyglucose F-18 positron emission
tomography (FDG-PET). A systematic review of the T staging
evaluation by EUS, CT and MRI showed a similar accuracy
between these techniques (65%–92.1%, 77.1%–88.9%, and
71.4%–82.6%, respectively). Serosal involvement assessment
also showed similar sensitivity and specificity across trials,
although it is specified that greater experience is available with
EUS [30].
CT remains the imaging method of choice for the evaluation
of local extension and of distant metastases. There is no
uniform consensus on the role of EUS, although there may be
an important role when a decision needs to be made regarding
preoperative treatment in patients with superficial disease or in
case of linitis plastica. In specific cases FDG-PET may offer
some additional information for inderterminate lesions to
verify or exclude metastases (mainly in GEJ tumors), although
it has been reported that up to one-third of metastatic gastric
cancers are FDG-PET negative, especially in the diffuse-type
histology [31–33]. A meta-analysis examining the detection of
liver metastases in colorectal, gastric and esophageal cancer
showed its advantage as compared with US, CT or MRI [31,
32]. MRI is not done routinely for the staging of gastric cancer.
A role for staging laparoscopy, eventually combined with
peritoneal lavage, has been suggested in the staging of gastric
cancer. Some series suggest up to 20% detection of unsuspected
peritoneal metastases, not diagnosed by CT [34, 35]. The
prognostic value of cytological examination of intraoperative
washings in potentially resectable gastric cancer remains
controversial. Hence, this technique has not been routinely
implemented in many of the centers especially with
preoperative chemotherapy incorporated as a therapeutic
option in resectable patients. Recommendations for staging by
the panel are presented in Figure 2.
treatment of resectable disease
adjuvant and neoadjuvant treatment
Several treatment strategies have been shown to be efficacious
in the treatment of non-metastatic gastric cancer and are
accepted as a standard of care option. There is a large regional
variation in the adjuvant and neoadjuvant treatment of gastric
cancer. The highest level of evidence is available for the strategy
of perioperative chemotherapy and postoperative
chemoradiotherapy. There is also some evidence for the benefit
of postoperative chemotherapy, mainly from recent meta-
analyses.
Indications for the use of adjuvant or neoadjuvant treatment
vary, but are mainly selected for T3/T4 and/or N-positive
tumors.
Perioperative chemotherapy has been implemented in most
European countries following the results of the MAGIC trial.
The trial demonstrated an increase in 5-year OS from 23% to
36% with the perioperative (pre- and postoperative) ECF
[epirubicin, cisplatin, 5-fluorouracil (5FU)] regimen as
opposed to surgery alone [36]. Recently, two meta-analyses
examined the role of neoadjuvant chemotherapy versus
primary surgery; one demonstrated a 5-year OS hazard ratio
(HR) of 0.68 [95% confidence interval (CI) 0.48–0.97, P = 0.03]
in favor of chemotherapy [37]. The other with a survival HR of
0.82 (95% CI 0.73–0.91, P = 0.0002), performed a subset
analysis demonstrating an advantage only in GEJ tumors and
not in gastric tumors (P = 0.007, P = 0.31, respectively). The
researchers stated, however, that the power of the analysis was
too low to reach significance [38].
Based on the results of the REAL-2 trial in metastatic gastric
cancer, showing the non-inferiority of oxaliplatin compared
with cisplatin and of capecitabine compared with 5FU, the
panel believes these drugs are accepted alternatives for
perioperative treatment as well [39, 40]. A recently published
French study validated the concept of perioperative treatment
in gastric cancer with 5FU and cisplatin without epirubicin
[40]. Insufficient data are available to incorporate docetaxel or
biologicals in the perioperative setting.
Adjuvant chemotherapy is the current standard in East Asia.
The recent GASTRIC meta-analysis demonstrated an absolute
survival benefit of 5.8% at 5 years (from 49.6% to 55.3%) and
7.4% at 10 years (from 37.5% to 44.9%) with adjuvant
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chemotherapy compared with surgery alone. Overall HR of
death was 0.82 (95% CI 0.76–0.90; P < 0.001) [41]. The current
regimen implemented in Asia of S1 given for 1 year following
surgery, has shown a 3-year OS increase from 70% to 80%
when compared with surgery alone [42]. The most frequently
used regimens are S-1 in East Asia and Japan and a 5FU/platin-
based regimen in the West.
The INT0116 (SWOG 9008) randomized phase III trial is
the basis for the current adjuvant chemoradiotherapy often
used in the USA. The last update with >10 years follow-up
further substantiated the advantage of the 5FU plus
radiotherapy protocol over surgery alone. The HR for
survival was 1.32 (P = 0.004) and for disease-free survival
(DFS) 1.51 (P < 0.001) in favor of adjuvant
chemoradiotherapy. A subset analysis showed a benefit to all
subgroups with the exception of a diffuse-type histology [43].
There is no evidence yet that intensifying the chemotherapy
with the addition of other cytotoxics to 5FU improves the
outcome further. Postoperative chemoradiotherapy is
recommended for locally advanced patients demonstrating
on pathology-positive lymph nodes, positive margins,
inadequate staging or suboptimal surgery, if neoadjuvant
chemotherapy was not administered.
radiotherapy regimen
The standard radiotherapy protocol implemented in the
adjuvant treatment of gastric cancer reflects the schedule used
in the INT0116 (SWOG 9008) trial. Despite the use of bolus
5FU in the trial, the panel recommends the use of a continuous
infusion regimen, as this administration is more tolerable and
at least as effective. This has been recently incorporated in
several small trials that attempted to add different combination
cytotoxic agents to the protocol, without success until now
[44, 45].
Experience and a quality assurance system is required in the
planning of the radiotherapy fields with the use of modern
techniques such as three-dimensional conformal radiotherapy
(3D-CRT) or intensity-modulated radiation therapy (IMRT) to
reduce toxicity. A total dose of 45 Gy should be given in 25
fractions of 1.8 Gy. Delineation of volumes should comply with
the published guidelines from the Radiation Therapy Oncology
Group (RTOG) and European Organisation for Research and
Treatment of Cancer (EORTC) (including tumor bed, celiac
and upper para-aortic lymph nodes).
Preoperative radiotherapy has been limited to pilot studies. If
implemented, care should be taken as radiated volumes are
different from the postoperative ones [46].
nutritional scheme
A nutritional scheme adapted to each patient by a dietician is
advised. Caloric intake should aim at a minimum input of 1500
kcal/day. Following gastrectomy inadequate caloric intake or
postgastrectomy syndrome is frequent. Total gastrectomy will
require intramuscular vitamin B12 supplements. In the case of
postoperative chemoradiotherapy, a percutaneous enteral
feeding tube may be needed to maintain adequate caloric
intake.
GEJ adenocarcinoma
GEJ tumors are categorized according to the Siewert
classification into distal esophageal adenocarcinoma (Type I),
true carcinoma of the cardia (Type II) and subcardial gastric
cancer (Type III) [47]. Some series suggest that stage
distribution, as well as long-term survival rates, are different
amongst the different classes [48].
There is no consensus available on the treatment strategy of
GEJ adenocarcinoma. These tumors are incorporated in
esophageal cancer trials dominated by preoperative
•  Evaluation of organ function 
•  Tumor markers: CEA and CA 19-9: recommended 
•  Further technical examinations: 
Gastroscopy with biopsies 
Spiral CT scan abdomen with appropriate contrast and chest X-ray or preferably CT thorax 
EUS; no complete consensus, although there may be a role when a decision has to be taken 
on preoperative treatment in patients with superficial disease or in cases of linitis plastica 
 High resolution CT scan: same information as EUS 
No systematic role for MRI 
FGG-PET: very selected patients, mainly GE junction (1/3 of gastric cancers: PET negative) 
Staging laparoscopy ± peritoneal lavage: not done routinely because no clear therapeutic 
implications 
Figure 2. Recommended primary staging procedures.
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chemoradiation, as well as the gastric trials with their various
approaches, as specified earlier.
The German Oesophageal Cancer Study Group attempted
a phase III comparison between neoadjuvant chemotherapy
and neoadjuvant chemotherapy followed by
chemoradiotherapy in GEJ adenocarcinoma. The trial
unfortunately was closed early due to low accrual. The addition
of preoperative radiation increased the 3-year survival rate
from 27.7% to 47.4% but the study lacked the necessary power
for statistical significance (P = 0.07, HR 0.67, 95% CI 0.41–
1.07) [49] .
The strategy for the treatment of GEJ cancer can therefore be
guided by the ‘oesophageal’ approach, focusing on preoperative
chemoradiotherapy or by the ‘gastric’ approach with
perioperative chemotherapy or to a lesser extent postoperative
chemoradiotherapy. This has been thoroughly discussed
recently in a review by Power and Reynolds [50].
resection procedures for mucosal tumors
The choice of resection techniques for a mucosal tumor should
be based on a multidisciplinary discussion. A growing body of
evidence supports the use of EMR in mucosal tumors (Tis–
T1a), as only 3%–5% of these will demonstrate invaded lymph
nodes if gastrectomy with lymph node resection is performed.
When submucosal invasion (T1b) is present, lymph nodes are
involved in 25%–28% of patients. This would entail more
extensive surgery [51, 52]. Some series suggest that endoscopic
submucosal dissection (ESD) would reduce the risk of local
recurrence, which remains high with EMR (18% compared
with 3.7%, respectively, P < 0.001) although this has yet to be
proved in randomized clinical trials [53].
resection procedures for advanced, non-
metastatic tumors
Surgery is the cornerstone for curative treatment of
advanced, non-metastatic resectable gastric cancer. Several
Western studies have addressed the extent of
lymphadenectomy, comparing D1 with D2 lymph node
dissection [54–56]. Postoperative mortality was significantly
higher after a D2 dissection, while none of these studies
revealed an improvement in OS with D2 lymphadenectomy.
However, a recent update of the Dutch D1D2 study showed
that the gastric cancer-related death rate after a median
follow-up of 15.2 years was significantly higher in the D1
group (48%) compared with the D2 group (37%) [57]. A
small Italian study comparing D1 with D2 dissection found
very low 30-day mortality rates for both D1 and D2 lymph
node dissection (3.0% compared with 2.2%, P = 0.722) in
experienced centers [58], but survival results of this trial
have to be awaited. Other studies focus on procedural
volumes as markers for quality of care, and find lower
mortality rates and higher survival in centers with a high
annual caseload [59–61].
In Asian countries, D2 lymphadenectomy is considered
standard therapy for advanced resectable gastric cancer. A small
Taiwanese study compared D1 with D3 lymphadenectomy in
221 patients and found a significant improvement in 5-year
survival [62]. A Japanese study compared D2 with D2
combined with para-aortic node dissection and found no
difference in survival, with more surgery-related complications
in the para-aortic group [63].
Based on these results, D2 lymphadenectomy is the
recommended type of surgery, and should be performed in
experienced centers with high annual caseloads.
surveillance after treatment with curative intent
Several series examined the efficacy of a follow-up scheme or
early discovery of an asymptomatic recurrence in gastric cancer.
These studies showed no survival advantage [64, 65]. Therefore,
no systematic surveillance scheme can be proposed by the
panel. No randomized trials, however, attempted to answer this
dilemma especially in light of improved modern imaging
techniques and improved chemotherapy. Physicians may
therefore agree with the patients on an individual surveillance
program, taking into account the risk of recurrence, patient’s
expectations and concomitant pathology.
prognostic markers in resectable disease
Most series investigating possible prognostic factors in primary
gastric cancer validate the importance of the TNM staging
system [66–69]. Several studies showed a prognostic role for the
ratio between dissected nodes and involved ones [70, 71].
Elevated tumor markers, as well as tumor size and Lauren
histology, have been shown to be prognostic for recurrence and
survival in some series [68, 69, 72].
Asians with gastric adenocarcinoma have superior outcomes
in Los Angeles County. These outcomes verify disparities in
gastric cancer survival between different races and
ethnicities independent of established clinical and
pathologic factors [73].
Age has been suggested as a prognostic factor for recurrence
and survival following primary treatment of gastric cancer [70,
74]. However, in multivariate analyses, this was not an
independent factor [68, 72]. Other patient-related clinical
prognostic factors have also failed to show independent
prognostic significance in multivariate analysis in these series
[75]. However, the incorporation of these into a prognostic
nomogram did show a prognostic role.
The prognostic nomogram offered by MSKCC incorporated
age, sex, primary site (distal one-third, middle one-third, GEJ
and proximal one-third), Lauren histotype, number of positive
lymph nodes resected, number of negative lymph nodes
resected and depth of invasion. The predictive ability of the
nomogram was shown to be superior to TNM staging alone in
R0 tumors [76]. The nomogram, however, is not in common
clinical use, although the different variables suggested by it are
considered.
Series investigating MSI in gastric cancer patients suggest
a distinct phenotype characterized by older age, antral
localization of the tumor and intestinal Lauren subtype. The
prognostic correlation with survival, however, is conflicting
[77–80]. Preliminary results in small series suggest a prognostic
role for p53 expression [81, 82].
Recently a prognostic association was presented between
MMP-9 mRNA expression level and survival in metastatic
gastric cancer patients in an Arbeitsgemeinschaft Internistische
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Volume 22 | Supplement 5 | June 2011 doi:10.1093/annonc/mdr284 | v5
Onkologie (AIO) phase III cohort and a possible correlation
with chemotherapy resistance [83–85].
treatment of metastatic disease
first-line treatment
The administration of chemotherapy has a clear OS advantage
compared with best supportive care (BSC) (HR = 0.39; 95% CI
0.28–0.52) [86]. The advantage of combination versus single-
agent treatments, mainly 5FU, was also evident (HR = 0.83;
95% CI 0.74–0.93). It must be emphasized that this applies to
patients fit for clinical studies with preserved organ function
and a good performance status (PS).
The backbone of chemotherapy for patients with metastatic
gastric is 5FU and cisplatin. Following the REAL-2 and other
smaller trials [39, 87] demonstrating the non-inferiority of
capecitabine compared with 5FU and oxaliplatin compared
with cisplatin, the reference chemotherapy in the Western
world has become fluoropyrimidine/platinum based. The
FOLFOX regimen using biweekly oxaliplatin and continuous
infusion 5FU/folinic acid has shown safety advantages
compared with 5FU/cisplatin in several phase II trials [88–90].
In Japan and many Asian countries the reference treatment for
metastatic gastric cancer is often oral fluoropyrimidine, either
S1 or capecitabine based. It is, however, unclear whether S1 is
more active than the other fluoropyrimidines in Asian patients.
A small Korean study showed similar activity of S-1 and
capecitabine. Fit patients are treated in some Asian countries
with a capecitabine- or S-1-based doublet (most frequently
cisplatin) [91, 92]. The pharmacology of S-1 is different
between Asian and Caucasian patients [93]. Recently, the
FLAGS multinational phase III trial compared the S1/cisplatin
combination with 5FU/cisplatin in non-Asian patients. Similar
efficacy was noted with an improved toxicity profile when S1
was administered; including less grade 3/4 neutropenia and
fewer treatment-related deaths (32.3% compared with 63.6%,
2.5% compared with 4.9%; P < 0.05, respectively) [94].
Docetaxel added to 5FU/cisplatin increases the activity
compared with the doublet 5FU/cisplatin according the V325
study: longer progression-free survival, OS and a higher
response rate are reported for the triplet cytotoxic combination
compared with the doublet [95]. The high toxicity of the three
weekly regimen leads, however, to recommendations to add
docetaxel only in selected patients with a good PS and good
organ function and using a modified regimen with reduced
dose, or with weekly or biweekly regimens or integrating
oxaliplatin instead of cisplatin [96].
There was also agreement among the experts, based on the lack
of demonstration of the additional activity of epirubicin in
combination regimens, to not recommend systematically
epirubicin in combination regimens formetastatic gastric cancer.
It was recommended by the panel to test metastatic gastric
adenocarcinoma for HER2. In the ToGA (Trastuzumab for
GAstric cancer) study, from 3665 analyzed tumor samples, 810
(22.1%) were HER2 positive according to protocol
requirements (IHC 3+ or FISH positive). Rates of HER2
overexpression/amplification were similar between patients
from Europe and Asia, but higher in patients with intestinal
versus diffuse-type tumors (32.0% versus 6.1%) and GEJ versus
gastric tumors (32.2% versus 21.4%). In the ToGA trial
trastuzumab was added to chemotherapy (fluoropyrimidine,
either 5-FU or capecitabine plus cisplatin) in patients with
advanced gastric or GEJ cancer (n = 584) with overexpression
/amplification of HER2. The primary endpoint was OS. The
combination of chemotherapy plus trastuzumab was shown to
be statistically superior to chemotherapy alone, with an
increased median OS of nearly 3 months (13.8 compared with
11.1 months without trastuzumab). Moreover, increased
benefit from trastuzumab was seen in patients who had higher
levels of HER2 protein expression, including subgroups with
IHC score 2+/FISH+ and IHC score 3+. In these patients,
median OS increased from 11.8 months for the chemotherapy
treatment arm to 16.0 months for the chemotherapy with
trastuzumab arm. The combination of chemotherapy plus
trastuzumab also prolonged the progression-free survival and
increased the response rate without adding clinically relevant
toxicity to the treatment [97].
All patients with metastatic gastric adenocarcinoma who are
candidates for first-line chemotherapy should therefore be
tested for HER2-neu status and patients with a tumor
overpresssing the HER2 receptor should be treated with the
cisplatin/fluoropyrimidine plus trastuzumab combination.
Trastuzumab does not increase the toxicity of the
chemotherapy backbone. It is, however, not advised to combine
trastuzumab with anthracyclines based on increased cardiac
risk observed in breast cancer patients [98].
HER2-neu-negative patients should be considered for
combination therapy. The choice between a doublet or a triplet
combination should be directed by PS, general condition of the
patient and the expectations and wishes of the patient. In
elderly patients a single-agent regimen (fluoropyrimidine) can
be considered, although a combination regimen can also be
considered for fit patients [99].
Other targeted biological agents are at the moment still
investigational. The recently presented AVAGAST trial
investigating first-line capecitabine and cisplatin plus
bevacizumab or placebo failed to show a statistically significant
survival advantage in the intent to treat population, although
the progression-free survival and response rate were improved
with the addition of the anti-VEGF antibody. Moreover,
a geographical difference was found and in the subset analysis
of European and American patients a significant survival
advantage was found, but not in Asian patients [100]. The
addition of cetuximab to a cytotoxic doublet is currently being
investigated in the phase III EXPAND trial.
second-line treatment
Administering second-line therapy is accepted in most centers
for selected patients with a good performance status. Only an
early stopped German randomized clinical trial of irinotecan
plus BSC against BSC has been conducted in this setting. The
trial was early stopped due to low-rate recruitment, but it
showed a median OS of 2.4–4.0 months (HR 0.48; 95% CI
0.23–0.92; P 0.023 [101].
Accepted variables predicting survival with second-line
treatment are PS, baseline hemoglobin levels, time to
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progression (TTP) on first-line chemotherapy [102–104]. An
analysis published by an Italian group exploring the clinico-
pathologic variables predicting a survival analysis found PS 2,
hemoglobin £11.5 g/l, CEA >50 ng/ml, three or more metastatic
sites, TTP in first-line treatment of £6 months to be
independent of adverse prognostic factors for survival. Having
no risk factors resulted in 12.7 months median OS while having
three or more resulted in 3.3 months [102].
The choice of agents to be given in second-line therapy
depends on earlier lines with acceptable options being
irinotecan [101], FOLFIRI (irinotecan, 5FU/folinic acid) [105],
docetaxel [106] and paclitaxel [107, 108].
In some trials second-line therapy has been more frequently
used in East Asia including Japan and Korea compared with
Western countries. Longer survival of Asian patients in some
trials was at least in part attributed to more common use of
second-line therapy.
Further lines can be discussed with patients in good
performance status although evidence of efficacy is lacking. The
combination of mitomycin C and capecitabine is optional again
with little evidence [109]. Participation in clinical trials should
be encouraged.
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